Beximco Pharmaceuticals (DHA:BXPHARMA) Research & Development: BDT-157 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:BXPHARMA Beximco Pharmaceuticals PLC DHA:BXPHARMA
94 GF Score
Price BDT150.90
GF Value BDT128.18
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Beximco Pharmaceuticals Research & Development?

Beximco Pharmaceuticals DHA:BXPHARMA +2.58% 94 Research & Development is BDT-157 Mil as of Mar. 2026. GuruFocus rates DHA:BXPHARMA with a GF Score™ of 94/100 and a GF Value™ of BDT128.18 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Beximco Pharmaceuticals's Research & Development for the three months ended in Mar. 2026 was BDT0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was BDT-157 Mil.

Beximco Pharmaceuticals  (DHA:BXPHARMA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Beximco Pharmaceuticals Research & Development Related Terms

Beximco Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Beximco Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beximco Pharmaceuticals Research & Development Chart

Beximco Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.49 6.95 2.91 3.00 8.55

Beximco Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -198.42 41.57 0.00 0.00
DHA:BXPHARMA
94GF Score
Beximco Pharmaceuticals PLC DHA:BXPHARMA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beximco Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-157 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of BDT-157 Mil mean?
Beximco Pharmaceuticals (DHA:BXPHARMA) has a Research & Development of BDT-157 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Beximco Pharmaceuticals and its competitors.
Is Beximco Pharmaceuticals' Research & Development too high?
Beximco Pharmaceuticals' current Research & Development is BDT-157 Mil. Overall, Beximco Pharmaceuticals has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' Research & Development compare to ZTS and UTHR?
Beximco Pharmaceuticals' Research & Development of BDT-157 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Beximco Pharmaceuticals and its competitors. Beximco Pharmaceuticals's current Research & Development is BDT-157 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Beximco Pharmaceuticals (DHA:BXPHARMA) is currently considered Modestly Overvalued. The stock's GF Value™ is BDT128.18, compared to a current price of BDT150.90 — trading 17.7% above its estimated fair value. The current Research & Development is BDT-157 Mil. Beximco Pharmaceuticals' overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Beximco Pharmaceuticals (DHA:BXPHARMA), the current Research & Development is BDT-157 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beximco Pharmaceuticals (DHA:BXPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Beximco Pharmaceuticals stock appears to be overvalued. The current stock price of BDT150.90 is trading 17.7% above its estimated GF Value™ of BDT128.18. GuruFocus considers Beximco Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for DHA:BXPHARMA:

  • Research & Development: BDT-157 Mil
  • GF Value™: BDT128.18 vs. price of BDT150.90 (17.7% above fair value)
  • GF Score™: 94/100 with 5 warning signs

No single metric tells the full story. See the DHA:BXPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beximco Pharmaceuticals Business Description

Other Exchanges BXP:UKR2WA:Germany
Address 19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
94GF Score

Get the complete analysis for DHA:BXPHARMA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT150.90
Price
BDT128.18
GF Value